Larry J Copeland, MD
Leadership Title: William Greenville Pace III and Joann Norris Collins-Pace Chair for Cancer Research
Academic Title: Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a gynecologic oncologist specializing in ovarian, uterine, endometrial, cervical and other female cancers. I received my medical training from the University of Western Ontario and completed my residency in obstetrics and gynecology at McMaster University. I’ve been named to Woodward White Inc.’s "Best Doctors in America" list since 1992 and was rated in the top 10 percent of physicians in the nation for patient satisfaction in 2016. I was also named to the Castle Connolly list of “America's Top Doctors” from 2000-2019. I am a member of the Translational Therapeutics Program at the OSUCCC – James and have served in leadership roles in several national organizations, including the Society of Gynecologic Oncology, the American Board of Obstetrics and Gynecology, and the American Gynecological and Obstetrical Society. Since 2017, I have served as president of the GOG Foundation, a group who leads clinical research in patients with gynecological cancers in the United States and networks with global partners. I also hold the William Greenville Pace III and Joann Norris Collins-Pace Chair for Cancer Research. At the OSUCCC – James, I strive to provide my patients with state-of-the-art treatment. With the cutting-edge technology and research facilities available at The James, I feel I can give them the best individualized care possible. I am proud to be working towards a cancer-free world.
Clinical Expertise
More info for- Cervical Cancer
- Gynecologic Cancers
- Reproductive Health
- Women's Health
- Vaginal Cancers
- Soft Tissue Cancers
- Endometrial Cancers
- Ovarian Cancers
- Vulvar Cancers
- Uterine Cancers
- Peritoneal Cancers
Research Interests
More info for- Sarcoma
- Carcinoma
- Neoplasms
- Neutropenia
- Endometrial Neoplasms
- Adenocarcinoma
- Neoplasm Metastasis
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Colorectal Neoplasms, Hereditary Nonpolyposis
Where I See Patients
More info forThe James Gynecologic Oncology Mill Run
3651 Ridge Mill Drive Hilliard, Ohio 43026 614-293-3873 Location InformationEducation & Training
More info forResidency - Obstetrics & Gynecology
- McMaster University Medical Center
1280 Main St West, Hamilton, ON
Fellowship - Obstetrics & Gynecology
- University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX
Medical School
- University of Western Ontario
1151 Richmond St North, London, ON
- McMaster University Medical Center
Academic Office & Contact Information
More info forAcademic Office:
320 W 10th Ave
Columbus, Ohio 43210-1280Phone:
614-438-8787Email:
copeland.7@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Publications
More info forJuly 11, 2024A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA
Future Oncol
July 1, 2024Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
Graybill WS, Pardo Búrdalo B, O'Malley DM, Vergote I, Monk BJ, Auranen A, Copeland LJ, Sabbatini R, Herzog TJ, Follana P, Pothuri B, Braicu EI, McCormick C, Yubero A, Moore RG, Vuylsteke P, Raaschou-Jensen N, York W, Hartman J, González-Martín A
Int J Gynecol Cancer
April 1, 2024Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
March 29, 2024Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
January 24, 2024Changes in prospectively collected patient-reported outcomes among women with incident endometrial cancer.
Sinnott JA, Torkashvand E, Meade CE, Salani R, Vetter MH, Hall B, Skolnick R, Bixel KL, Cohn DE, Cosgrove CM, Copeland LJ, Hebert C, Felix AS
J Cancer Surviv
January 22, 2024Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ
Gynecol Oncol
December 21, 2023Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
Chan JK, Tian C, Kesterson JP, Lin KY, Darcy K, Richardson MT, Kapp DS, Monk BJ, McNally L, Landrum L, Copeland L, Walker JL, Wenham RM, Phippen N, Spirtos NM, Tewari K, Shahin M, Berry L, Bell JG
Gynecol Oncol
September 21, 2023The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Haight PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, Backes FJ, Bixel KL, Copeland LJ, Cohn DE, Cosgrove CM, O'Malley DM, Nagel CI, Spakowicz DJ, Chambers LM
Gynecol Oncol
July 1, 2023Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Pothuri B, Blank SV, Myers TK, Hines JF, Randall LM, O'Cearbhaill RE, Slomovitz BM, Eskander RN, Alvarez Secord A, Coleman RL, Walker JL, Monk BJ, Moore KN, O'Malley DM, Copeland LJ, Herzog TJ
Gynecol Oncol
April 8, 2023Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Levine MD, Barrington DA, Meade CE, Lammers SM, McLaughlin EM, Suarez AA, Backes FJ, Copeland LJ, O'Malley DM, Cosgrove CM, Cohn DE, Nagel CI, Felix AS, Bixel KL
Gynecol Oncol
April 1, 2023Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
Piver RN, Wagner VM, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Gynecol Oncol Rep
April 1, 2023FIGO IVB vaginal cancer with non-contiguous rectal metastasis treated with definitive chemoradiation: A case report.
Fort M, Yaney A, Copeland L, Quick A
Gynecol Oncol Rep
April 1, 2023Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Levine MD, O'Malley DM, Haight PJ, Senter L, Wagner V, Bixel KL, Cohn DE, Copeland LJ, Cosgrove CM, McLaughlin EM, Backes FJ
Gynecol Oncol Rep
March 27, 2023Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA, RUBY Investigators
N Engl J Med
December 24, 2022Postoperative Venous Thromboembolism Risk Stratification in Patients with Uterine Cancer.
Wagner VM, Piver RN, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Am J Obstet Gynecol
December 23, 2022Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland LJ, Monk BJ, Coleman RL, Herzog TJ, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter AO, Childs BH, Elbi C, Bulat I
Int J Gynecol Cancer
September 22, 2022The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
Riedinger CJ, Patterson JM, Backes FJ, O'Malley D, Bixel KL, Copeland LJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Gynecol Oncol
August 2, 2022Less is more: Clinical utility of postoperative labs following minimally invasive hysterectomy for endometrial cancer.
Lightfoot MDS, Felix AS, Calo CA, Hosmer-Quint JT, Taylor KL, Brown MB, Salani R, Copeland LJ, O'Malley DM, Bixel KL, Cohn DE, Fowler JM, Backes FJ, Cosgrove CM
Am J Obstet Gynecol
August 1, 2022High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.
Calo CA, Barrington DA, Brown M, Gonzalez L, Baek J, Huffman A, Benedict J, Backes F, Chambers L, Cohn D, Copeland L, Cosgrove C, Nagel C, O'Malley D, Bixel K
Gynecol Oncol Rep
July 11, 2022What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M, Herzog TJ, Monk BJ, Backes F, Secord AA, Bonebrake A, Rose PG, Tewari KS, Lentz SS, Geller MA, Copeland LJ, Mannel RS
Gynecol Oncol
June 27, 2022Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, O'Malley DM, Street DG, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, Dewdney SB, Spirtos NM, Lele SB, Guntupalli S, Ueland FR, Glaser GE, Mannel RS, DiSaia PJ
J Clin Oncol
June 1, 2022In Reply.
Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, Robertson S, Copeland LJ, Walker JL, Wenham R, Casablanca Y, Spirtos NM, Tewari KS, Bell JG
Obstet Gynecol
April 20, 2022Practice changing cervical cancer clinical trials.
Pothuri B, Eskander RN, Randall LM, O'Malley DM, Slomovitz B, Moore KN, Herzog TJ, Coleman RL, Copeland LJ, Monk BJ
Gynecol Oncol
January 10, 2022Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS
J Clin Oncol
January 6, 2022Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.
Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, Robertson S, Copeland LJ, Walker JL, Wenham RM, Casablanca Y, Spirtos NM, Tewari KS, Bell JG
Obstet Gynecol
November 1, 2021Wound complications following vulvar excision for nonmalignant lesions.
Boyles GP, Weaver AM, Cohn DE, Backes FJ, Copeland LJ, Bixel KL, Fowler JM, O'Malley DM, Cosgrove CM
AJOG Glob Rep
August 17, 2021Endometrial Cancer: Who lives, who dies, can we improve their story?
Cosgrove CM, Backes FJ, O'Malley D, Bixel KL, Suarez AA, Fowler JM, Copeland LJ, Goodfellow PJ, Cohn DE
Oncologist
August 1, 2021Cervical carcinoma with histologic components of sarcomatoid carcinoma and multiple basaloid variants: A case report and review of the literature.
Haight PJ, Castaneda AV, Savage JM, Copeland LJ
Gynecol Oncol Rep
July 13, 2021Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D
Gynecol Oncol
March 12, 2021The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
Monk BJ, Coleman RL, Herzog TJ, Moore KN, O'Malley DM, Randall LM, Slomovitz BM, Eskander R, Pothuri B, Reese LL, Mannel RS, Copeland LJ
Gynecol Oncol
January 27, 2021Standing on the shoulders of giants: Mentorship advice from leaders in the field.
Boitano TKL, Chi DS, Copeland LJ, Straughn JM
Gynecol Oncol
January 1, 2021Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
Hampel H, Pearlman R, de la Chapelle A, Pritchard CC, Zhao W, Jones D, Yilmaz A, Chen W, Frankel WL, Suarez AA, Cosgrove C, Backes F, Copeland L, Fowler J, O'Malley D, Salani R, McElroy JP, Stanich PP, Goodfellow P, Cohn DE
Gynecol Oncol
September 1, 2020Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM
Surg Oncol
May 23, 2020Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer - a potential management strategy in the era of COVID-19.
Vetter MH, Smrz SA, Copeland LJ, Cohn DE
Am J Obstet Gynecol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Copeland has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- GOG Foundation, Inc.
Patient Comments
Dr. Copeland and staff are exemplary care providers.
Dr. Copeland and Sarah S. Are the best!
There were some anomalies on my CT scans this time. Dr. Copeland discussed them with me. I am satisfied with the plan to continue to monitor the areas.
The care providers are amazing. They actually do care and listen to you.
Good
Dr Copeland was concerned and thoughtful. He said he Is aggressive and we think that is a good trait for a cancer doctor.
The nurses,staff,and doctors are amazing and so polite. They explained everything to me so I wasn't or didn't have any reason to be as scared as I was.
I was so happy I could see Dr Copeland again
Staff provide excellent care and are very concerned for the patient.
I had the best personal, reassuring, one on one talk with a doctor. His assistant of 20 years was perfect and professional. Great team and atmosphere for reassurance and calming.
Genuine concern, test results super, physical exam efficient & painless; process for follow-up over upcoming years clearly explained.